A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
众所周知,糖尿病足是糖尿病的严重并发症,也是糖尿病致残、致死率最高的并发症。血管狭窄闭塞、神经病变和感染是主要的临床表现。其早期临床表现包括,皮肤营养不良、干燥、无汗、变脆而五弹性、毛发脱落、溃破、坏疽等。哪些人糖尿病足高危人群:
糖尿病足病高危人群包括,存在周围神经病变和周围血管病变的患者;有足部溃疡史者;足部畸形,如爪形趾、夏科氏足;胼胝形成;失明或视力下降;肾脏病变(尤其是慢性肾功能衰竭);老年(尤其指独身者);难以独立触及足部者;缺乏糖尿病的相关知识者;Semmes-Weinstein单尼龙丝(SWM)测定结果阳性者。
糖尿病性肢体缺血症的病理生理变化是由于代谢紊乱所引起的微血管和大中小血管的病变以及神经系统的功能障碍,加上糖尿病免疫功能受损,易于发生感染。一般与以下4个方面有关:
(1)糖尿病患者足底压力的变化:动态足底压力异常增高与糖尿病足底溃疡的发生明显相关,足底压力增高作为足溃疡的预测因子,具有很高的特异性;(2)血管病变:大血管病变,大血管病变是指大,中动脉病变而言,主要发生于腹主动脉、心脑和肢体主干动脉。对由于血管病变所引起的糖尿病性肢体缺血症,临床上多称为糖尿病动脉闭塞症;(3)神经系统功能障碍:
糖尿病患者由于大血管病变和微血管病变,营养神经的血管出现功能和器质性改变,引起神经营养障碍和缺血性神经炎;
(4)感染:
感染不是糖尿病足的主要原因,却是促使其加重的一个重要因素。糖尿病患者由于肌体免疫力低下,白细胞的游走性和吞噬能力降低,使其易于发生感染且难以控制。缺血的肢体更易于发生感染,且多为革兰阴性菌感染,感染后使血液中促凝物质增加,局部氧耗增加,使局部缺血加重而发生坏疽。
五步严防糖尿病足
糖尿病足是糖尿病患者因末梢神经病变、下肢动脉血供不足以及感染等多种因素引起足部疼痛、皮肤溃疡、肢端坏疽等病变的统称。糖尿病足主要由于糖尿病造成肢体周围血管、神经病变继发感染所致,而控制血糖是减缓周围血管、神经病变发生的有效手段。并且高血糖也易发生感染,所以严格控制血糖是非常关键的一步。
糖尿病专家建议,按照如下五步走或可严防糖尿病足:
一、预防大于治疗。糖尿病足还是以预防为止,尽量避免足部受损,比如穿合适松软的不露脚趾的平底鞋、布鞋,避免用过热的水泡脚,冬天不要用热水袋暖脚等。
二、严格控制血糖。并发症的源头是因为血糖过高,所以,严格控制血糖是治疗糖尿病的基础。如果血糖波动的大,必要时可采用胰岛素强化治疗,可导致缓解症状。此外,还要控制血压和血脂。
三、定期去医院做足部检查。如有破损赶紧治疗,糖尿病足有时候发展很快,短短几天就无可挽回。所以,及时进行下肢血管检测是非常必要的。
四、静脉输注。糖尿病足是因为血管堵塞和神经病变综合因素影响而导致的,所以,对血管阻塞不是非常严重工没有手术指征的患者,可以采用静脉输注的办法,输注一些扩血管和改善血液循环的药物,也能有效防止糖尿病足的发生和发展。
五、积极治疗感染。有足部溃疡的患者,要积极治疗,可根据细胞培养和药敏试验选用合适的抗生素。对一些较难治的溃疡,如果影响到整个或大部分足部,应该考虑截肢治疗,以保证生命安全。
糖尿病足不容忽视,它的症状表现多样,很容易让人混淆。希望您时刻关注脚部变化,如有不良症状立即就医,不可贸然采取治疗措施。另外,糖尿病足的发病根源是血糖,控制血糖稳定仍然是糖尿病患者的当务之急。
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。